IGF1R and metabolic syndrome: The IGF-1R antibody therapy resulted in hyperglycemia and metabolic syndrome, and the receptor tyrosine kinase inhibitors manifested metabolic toxicities, most likely due to high similarity between IGF-1R and insulin receptor [47].